Back to results
US 8,278,058 B2Granted
Diagnostic composition and kit for renal cell carcinoma
AssigneesDCD, Ltd., Genomine, Inc.
InventorsDong Su Kim, Nam Hoon Cho, Hyung Jin Na, Young Deuk Choi, Jae Ho Jang, Hye-Kyung Kim, Mo Yoel Park, Won Man Park, Tae-hoon Kim, Dong Hee Lee, Kyung Mok Park
Life of this patent
Estimating the term…
Abstract
Disclosed herein are a composition and a kit for diagnosing renal cell carcinoma. The composition and kit employ, as a renal cell carcinoma marker, nicotinamide N-methyltransferase, L-plastin, secretagogin, NM23A, CapG, which is an actin regulatory protein, and/or C4a anaphylatoxin.
Claims9
A method for diagnosing renal cell carcinoma in a patient comprising steps of:
- preparing a composition containing a binding molecule that specifically binds NNMT protein;
- contacting the composition with a biological sample from a patient to measure expression level of NNMT protein, wherein the biological sample is a sample selected from the group consisting of a blood sample, a serum sample and a plasma sample;
- and
- comparing the expression level of NNMT protein in the biological sample from the patient with the expression level of NNMT protein in a corresponding biological sample from a normal individual;
- and
- classifying a patient with an elevated expression level of NNMT protein as having renal cell carcinoma.
3 more elements
Dependencies are inferred from the claim text.